ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · MONDO_0011786

allergic rhinitis

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. allergic rhinitis. Diseases, record MONDO_0011786. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0011786

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
allergic rhinitis
Open Targets
Open Targets ID
MONDO_0011786
Open Targets
Other names
AR, allergic form of rhinitis
Open Targets
Disease Ontology
DOID:4481
Disease Ontology
NCI Thesaurus
C79532
NCI Thesaurus
Highest stage of its drugs
Approval, for 49 of its 123 drugs, from DailyMed, PMDA and TTD
Open Targets

Drugs123

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
FLUTICASONE PROPIONATECHEMBL1473Small moleculeApprovalDailyMed412120Drugs and targets
MOMETASONE FUROATECHEMBL1161Small moleculeApprovalDailyMed and PMDA242020Drugs and targets
DESLORATADINECHEMBL1172Small moleculeApprovalDailyMed, PMDA and TTD321616Drugs and targets
MONTELUKASTCHEMBL787Small moleculeApprovalDailyMed161514Drugs and targets
BUDESONIDECHEMBL1370Small moleculeApprovalDailyMed161111Drugs and targets
FLUTICASONE FUROATECHEMBL1676Small moleculeApprovalDailyMed and PMDA161111Drugs and targets
CETIRIZINECHEMBL1000Small moleculeApprovalTTD121111Drugs and targets
LORATADINECHEMBL998Small moleculeApprovalDailyMed141010Drugs and targets
AZELASTINE HYDROCHLORIDECHEMBL1200809Small moleculeApprovalDailyMed13109Drugs and targets
FLUTICASONECHEMBL1201396Small moleculeApprovalTTD766Drugs and targets

1 to 10 of 123

See all 123 drugs

Targets53

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
HRH1Histamine H1 receptor34Histamine H1 receptor antagonist; Histamine H1 receptor inverse agonistApprovalhttps://conductscience.org/library/genes/3269Drugs and targets
NR3C1Glucocorticoid receptor21Glucocorticoid receptor agonistApprovalhttps://conductscience.org/library/genes/2908Drugs and targets
ADRA1AAdrenergic receptor5Adrenergic receptor agonist; Adrenergic receptor alpha agonist; Adrenergic receptor alpha-1 agonistApprovalhttps://conductscience.org/library/genes/148Drugs and targets
ADRA1BAdrenergic receptor5Adrenergic receptor agonist; Adrenergic receptor alpha agonist; Adrenergic receptor alpha-1 agonistApprovalhttps://conductscience.org/library/genes/147Drugs and targets
ADRA1DAdrenergic receptor5Adrenergic receptor agonist; Adrenergic receptor alpha agonist; Adrenergic receptor alpha-1 agonistApprovalhttps://conductscience.org/library/genes/146Drugs and targets
PTGDR2Prostaglandin D2 receptor 24G protein-coupled receptor 44 antagonistPhase 2https://conductscience.org/library/genes/11251Drugs and targets
ADRA2AAdrenergic receptor3Adrenergic receptor agonist; Adrenergic receptor alpha agonistApprovalhttps://conductscience.org/library/genes/150Drugs and targets
ADRA2BAdrenergic receptor3Adrenergic receptor agonist; Adrenergic receptor alpha agonistApprovalhttps://conductscience.org/library/genes/151Drugs and targets
ADRA2CAdrenergic receptor3Adrenergic receptor agonist; Adrenergic receptor alpha agonistApprovalhttps://conductscience.org/library/genes/152Drugs and targets
HRH3Histamine H3 receptor3Histamine H3 receptor antagonistPhase 2https://conductscience.org/library/genes/11255Drugs and targets

1 to 10 of 53

See all 53 targets

Trials186

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 9 more are not shown, since the checks do not confirm them.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT00761527Observation of Side Effects and Effectiveness of Desloratadine (Aerius) Syrup in Filipino Children (Study P05634)2,9802012-03-01Rhinitis, Allergic, Seasonal, Rhinitis, Allergic, Perennial, UrticariaDESLORATADINEIts record names the diseaseClinicalTrials.gov
NCT00783432Study to Evaluate the Safety and Tolerability of a Nasal Spray in Patients With Chronic Allergic or Nonallergic RhinitisPhase 38622009-10-02Chronic Allergic Rhinitis, Nonallergic RhinitisAZELASTINE HYDROCHLORIDEOpen Targets' reading of its recordClinicalTrials.gov
NCT01067105A 6 Month Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and OlderPhase 38242012-06-11Perennial Allergic RhinitisCICLESONIDEIts record names the diseaseClinicalTrials.gov
NCT00405964Study for the Treatment of Persistent Allergic Rhinitis With Desloratadine (Study P04684)Phase 37162010-11-19Allergic RhinitisDESLORATADINEIts record names the diseaseClinicalTrials.gov
NCT01918033A Study of the Efficacy and Safety of Desloratadine (MK-4117) in Japanese Participants With Perennial Allergic Rhinitis (MK-4117-200)Phase 36082014-08-15Perennial Allergic RhinitisDESLORATADINEIts record names the diseaseClinicalTrials.gov
NCT01425632A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic RhinitisPhase 34902015-12-14Perennial Allergic RhinitisBEPOTASTINE BESYLATEIts record names the diseaseClinicalTrials.gov
NCT04981717A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a CatPhase 34462024-06-11Allergic Rhinitis Due to Cat AllergyFRENESLERBARTIts record names the diseaseClinicalTrials.gov
NCT017947413 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic RhinitisPhase 34052015-03-31Allergic RhinitisAZELASTINE HYDROCHLORIDE, FLUTICASONE PROPIONATEIts record names the diseaseClinicalTrials.gov
NCT01231464A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent Subjects With Allergic RhinitisPhase 33652011-02-04Rhinitis, Allergic, Perennial, Allergic RhinitisFLUTICASONE FUROATEIts record names the diseaseClinicalTrials.gov
NCT02424539A Study to Compare the Efficacy and Safety of Fluticasone Furoate Nasal Sprays (FFNS) 55 Microgram (mcg) and 110 mcg in Chinese Pediatric Subjects With Allergic Rhinitis (AR)Phase 43582019-02-06Rhinitis, Allergic, Perennial and Seasonal, Rhinitis, AllergicFLUTICASONE FUROATEIts record names the diseaseClinicalTrials.gov

1 to 10 of 186

See all 186 trials

Comparisons in its trials40

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
Astepro Nasal Spray vs Astelin Nasal Spray: Number of Participants Reporting Adverse Events207 of 428211 of 430858NCT00783432Trial comparisons
5-mg Desloratadine Tablet vs Placebo Tablet: serious adverse events1 of 3602 of 356716NCT00405964Trial comparisons
Phenylephrine HCl ER, 30 mg vs Phenylephrine HCl IR, 10 mg: serious adverse events0 of 3270 of 324651NCT00976209Trial comparisons
Ciclesonide vs Mometasone: The Number of Subjects Experiencing AEs90 of 31167 of 312623NCT01401465Trial comparisons
Ciclesonide vs Mometasone: The Number of Subjects Experiencing Nasal AEs, Including Epistaxis, Nasal Ulceration, and Nasal Perforation6 of 3114 of 312623NCT01401465Trial comparisons
Ciclesonide vs Mometasone: serious adverse events0 of 3112 of 312623NCT01401465Trial comparisons
FF 110 µg vs MF 200 µg: serious adverse events0 of 2980 of 298596NCT02397915Trial comparisons
REGN1908-1909 vs Placebo: Number of Participants With Treatment-emergent Adverse Events (TEAEs) Throughout the Study2 of 2242 of 222446NCT04981717Trial comparisons
REGN1908-1909 vs Placebo: Number of Participants With Adverse Event of Special Interests (AESIs) Throughout the Study2 of 2240 of 222446NCT04981717Trial comparisons
REGN1908-1909 vs Placebo: Number of Participants With Serious Treatment-Emergent Adverse Events (TEAEs) Throughout the Study2 of 2242 of 222446NCT04981717Trial comparisons

1 to 10 of 40

See all 40 comparisons in its trials

Papers from its trials116

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
34429875RESULT1PubMed
34187620RESULT1PubMed
33647073RESULT1PubMed
33099797RESULT1PubMed
32679209RESULT1PubMed
31690374RESULT1PubMed
31179187RESULT1PubMed
30391954RESULT1PubMed
30239057RESULT1PubMed
30215894RESULT1PubMed

1 to 10 of 116

See all 116 papers from its trials

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0011786

GET https://conductscience.org/api/diseases/v1/MONDO_0011786/drugs?page=2

API referenceFor AI assistants